Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind,Dose-escalation Phase 1 Study to Assess the Safety, Tolerance, and Pharmacokinetics of Jaktinib,an Oral JAK2 Inhibitor, in Healthy Volunteers

Next Previous
Trial Profile

A Randomized, Double-blind,Dose-escalation Phase 1 Study to Assess the Safety, Tolerance, and Pharmacokinetics of Jaktinib,an Oral JAK2 Inhibitor, in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gecaxitinib hydrochloride (Primary)
  • Indications Autoimmune disorders; Cancer; Myelofibrosis
  • Focus Adverse reactions
  • Sponsors Suzhou Zelgen Biopharmaceuticals

Most Recent Events

  • 28 Feb 2019 Status changed from recruiting to completed.
  • 02 Aug 2018 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.
  • 02 Aug 2018 Planned primary completion date changed from 1 Nov 2017 to 30 Aug 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top